1、 2011 6 2 013 6 82 , , , , (PSA) , (P0.05) , 3 6 9 12 , , PSA (P0.05) .The PSA levels of patients in research group significantly decreased after treatment for 3, 6, 9 and 12 months, as compared with those in control group (P0.05) 1.2 , , (PSA) 3 ( CORDEN PHARMA GMBH, :J20150050, 50 mg*28 ) , 50 mg/
2、 , 1 /d, ( , J20160091, 3.6 mg/ ) , 3.6 mg/ , 1 /4 , 1 1 , 12 , , 4 1.3 : : , , PSA 1 ; : , , PSA 50%, 1 ; : , , PSA 50%, 0.05) 3 , , , 6 , , , , 7 , , , , , , , 8 , , , , , , (P0.05) 1 (%) Tab.1 Comparison of the clinical efficacy of patients between the two groupsn (%) 2 (%) Tab.2 The clinical sym
3、ptoms of patients with remission of contrast between the two groupsn (%) 3 PSA L) 4 (%) Tab.4 The adverse reaction rate of patients between the two groupsn (%) , , , , , , 9 , , PSA , , PSA (T) 10 , , , , , , , 11 , , , , , , 12 , , (P0.05) , PSA , , PSA , , 13 PSA , , PSA , 3 , PSA , 6 , , , PSA (P
4、0.05) , , , , , , , , 14 , , , , , , , , (P0.05) , , , , 12 , 15 , (P0.05) , , , , , 15 , , , PSA , , 1Qu JK.Clinical Evaluation of the Intermittent Treatment of Bicalutamide Combined with Goserelin for Locally Advanced Prostate CancerJ.China pharmaceut, 2016, 25 (11) :46-48. . J. , 2016, 25 (11) :4
5、6-48. 2Yang T.The curative effect of goserelin and bikalumide in treatment of advanced prostate cancerJ.J China Prescript Drug, 2016, 14 (5) :80-81. . J. , 2016, 14 (5) :80-81.doi:10.3969/j.issn.1671-945X.2016.05.057. 3Pang K, Zhou ZG, Huang YF, et al.Clinical efficacy and safety of bicalutamide com
6、bine with goserelin in the treatment of advanced prostate cancerJ.Chin J Clin Pharmacol, 2016, 5 (3) :224-226. , , , . J. , 2016, 5 (3) :224-226.doi:10.13699/ki.1001-6821.2016.03.010. 4Kaushik D, Kumar R, Khan S A, et al.Pharmacological screening for anti-inflammatory, analgesic activity of pyrazoly
7、l derivatives along with molecular docking studiesJ.Med Chem Res, 2015, 21 (11) :1-10.doi:10.1007/s00044-011-9901-0. 5Yu HB, Yu CL, Experiences of bicalutamide combined with goserelin in treatment of advanced prostate cancer in 78cases of patients with advanced prostate cancerJ.World Clin Med, 2015,
8、 6 (10) :18. , . 78 J. , 2015, 6 (10) :18. 6Zhu QJ.The clinical efficacy and safety evaluation of bicalutamide combined with goserelin in treatment of advanced prostate cancerJ.J North Pharm, 2017, 14 (5) :155. . J. , 2017, 14 (5) :155.doi:10.3969/j.issn.1672-8351.2017.05.133. 7Madhava G, Ramana KV,
9、 Sudhana SM, et al.Aryl/heteroaryl Substituted Celecoxib Derivatives as COX-2 Inhibitors:Synthesis, Anti-inflammatory Activity and Molecular Docking StudiesJ.Med Chem, 2017, 13 (5) :484-497.doi:10.2174/1573406413666170221093740. 8Li L, Han CD.Intermittent therapy of goserelin plus bicalutamide on se
10、rum VEGF and mi R-34a in patients with prostate cancerJ.Mod Instr Med Treat, 2014, 4 (2) :45-47. , . VEGF mi R-34a J. , 2015, 4 (2) :45-47.doi:10.11876/mimt201402013. 9Li J, Shi Y.Clinical observation of goserelin and triptorelin in treatment of advanced prostate cancerJ.J Clin Med Literat (Electron
11、ic Edition) , 2016, 3 (21) :4265-4266. , . J. , 2016, 3 (21) :4265-4266. 10Li ML.Clinical study on intermittent treatment of prostate cancer with bicalutamide and goserelinJ.J Mod Oncol, 2015, 23 (14) :2024-2026. . J. , 2015, 23 (14) :2024-2026.doi:10.3969/j.issn.1672-4992.2015.14.26. 11Saigal CS1,
12、Gore JL, Krupski TL, et al.Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancerJ.Cancer, 2007, 110 (7) :1493-1500. 12Ma M, Wu HX, Wu H, et al.Clinical effect of goserelin combined with bicalutamide on patients after metastatic prostate cancer operationJ.China M
13、ed, 2017, 12 (3) :403-406. , , , . J. , 2017, 12 (3) :403-406.doi:10.3760/cma.j.issn.1673-4777.2017.03.020. 13Henninge J, Pepaj M, Hullstein I, et al.Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparationJ.Drug Test Anal, 2010, 2 (11-12) :647-650.doi
14、:10.1002/dta.233. 14Li KQ.Analysis of curative effect of bicalutamide combined with chemotherapy in the treatment of castration resistant prostate cancerJ., 2015, 6 (10) :1224-1226. . J. , 2015, 6 (10) :1224-1226.doi:10.13455/ki.cjcor.2015.10.23. 15Chen LL, Xu T, Cui T et al.Clinical effects of bicalutanmide combined with chemotherapy in patients with castrationresistant prostate cancerJ.Chin J Clin Oncol Rehabil, 2015, 5 (9) :1099-1101. , , , . J. , 2016, 5 (9) :1099-1101.doi:10.13455/ki.cjcor.2016.09.21.
